Skip to Content

About Us
- Leadership
- Board of Directors
Our Approach
- Our Approach
- Scientific Publications
Pipeline
Investors & Media
Partnerships
Careers

Press Releases

Year

08.12.22

Terns Announces $65 Million Oversubscribed Offering

08.8.22

Terns Pharmaceuticals Reports Second Quarter 2022 Financial Results and Corporate Highlights

07.27.22

Terns Announces Appointment of Radhika Tripuraneni, M.D., M.P.H. to Board of Directors

06.22.22

Terns Pharmaceuticals Highlights Clinical Data from Multiple NASH Programs in Five Presentations at the EASL International Liver Congress™ 2022

06.8.22

Terns Pharmaceuticals to Present Clinical Data on Multiple NASH Programs at the EASL International Liver Congress 2022

06.1.22

Terns Pharmaceuticals Appoints Kerry Russell as Chief Medical Officer

05.16.22

Terns Pharmaceuticals Reports First Quarter 2022 Financial Results and Business Updates

04.4.22

Terns Pharmaceuticals to Present at the 21st Annual Needham Virtual Healthcare Conference

03.21.22

Terns Reports Top-line Results from Phase 1 AVIATION Trial of VAP-1 Inhibitor TERN-201

03.3.22

Terns Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Highlights

Pagination

Current page 1
Page 2
Next page
Last page

TERNS
1065 East Hillsdale Blvd., Suite 100
Foster City, CA 94404 (MAP)
info@ternspharma.com
investors@ternspharma.com
media@ternspharma.com
Phone: +1 650-525-5535 Ext.101
Fax: +1 650-275-4254

Site - Social

Site - Corporate

About Us
Our Approach
Pipeline
Investors & Media
Partnerships
Careers
Contact Us

© 2022 Terns Pharmaceuticals, Inc. Privacy Policy